Category: Clinical Research Transparency / GLP-1 Trends The buzz surrounding GLP-1 receptor agonists like semaglutide is undeniable. While initially celebrated for diabetes management and weight loss, headlines are now flooded with its potential to treat everything from dementia to addiction. But in an era of rapid scientific publishing and high media noise, how do clinicians, researchers, and stakeholders know which studies are truly foundational and which require a second look? One of the most talked-about recent studies: "Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial" published in The [keep reading...]